哪些补充类别吸引了FTC最多的关注

联邦贸易委员会执行行动中最常出现哪些补充类别?

减肥和饮食药补充剂是FTC历史最深层次的案例文件,从LeanSpa的果反抗到Sale Slash的加辛尼亚剑桥道,每案裁决数量达数亿.Genesis Today和 健康 公式在基础的减肥索赔本身上增加了宣誓证词欺诈和负选项计费.这种密度反映了几十年的积累案例法,而不是随机抽样的风险FTC的2022年产品健康指南更新.

Two newer categories are catching up fast. Compounded GLP-1 and peptide sellers now draw more federal letters in a single year than any classic weight-loss operator did in a decade: FDA's warning-letter database lists 139 letters citing semaglutide and 108 citing tirzepatide issued between 2024 and mid-2026. Multilevel-marketed mental-health claims (Amare Global, sued June 2026) and children's-health claims (TruHeight, April 2026) mark the newest expansion points into conditions FTC had not previously targeted at this volume.

相比之下,免疫支持的报价处于比较安静的执法区,记录中值得在自己的条件下理解的差距和 详细地图在这里.

无论哪种类型的索赔都会在这些案件中出现?

无论产品是什么,都会出现四种类型的索赔:假冒或未披露的来源证词,没有证据的戏剧性结果承诺,埋葬的负选项收费条款,以及制造的"独立"媒体报道. LeanSpa运行了虚假的CNN和福克斯新闻品牌;Sale Slash运行了虚假的奥普拉赞助;TruHeight支付员工五星级评价,同时运行了他们的后面的博特社交账户.

Where a case turns specifically on invented consumer voice rather than a product-mechanism dispute, penalties get calculated per violation rather than per campaign, which changes the exposure math considerably and is broken down here.

如何根据条件不同地应用健康声称证明标准?

FTC applies one formal standard everywhere but the practical bar shifts with how measurable the claim is. "Competent and reliable scientific evidence," defined in the 2022 guidance as research objectively evaluated and generally accepted in the relevant field, sounds uniform on paper. For weight loss specifically it isn't discretionary at all: FTC's Gut Check guide names seven claims — two or more pounds a week without dieting, permanent loss after stopping use, over three pounds a week for more than four weeks among them — that experts have already ruled impossible, so making any one of the seven is enforcement bait regardless of the study behind it.

Claims about harder-to-measure conditions such as mood, energy or immune resilience get judged instead on trial quality: guidance requires substantiation be "in the form of randomized, controlled human clinical testing," so animal or in-vitro data alone will not carry a copy line. Where an ingredient's story intersects a prescription drug — naming a GLP-1 brand next to a supplement claim, for instance — 21 CFR 101.93(g)(2) treats the reference itself as evidence of an implied disease claim, turning an FTC advertising problem into an FDA drug-classification problem in the same sentence. The gap between an aggressive but defensible claim and that line is exactly what a claim-by-claim breakdown of the substantiation threshold tracks.

哪些位吸引了FDA的警告信件而不是FTC的行动,为什么?

Peptides and compounded GLP-1 drugs draw FDA warning letters almost exclusively, and the underlying mechanism arguably makes this the more dangerous track for an operator, not the lesser one. FDA never has to prove a claim was false, only that marketing context shows intended human use. Under 21 CFR 201.128, intended use turns on labeling claims, advertising and "the circumstances surrounding the distribution of the article," so a "research use only" disclaimer changes nothing if the product page describes weight-loss mechanism of action — precisely what FDA cited against Gram Peptides in March 2026.

包装复制供应进一步加剧了暴露:FDA在同一封Gram Peptides信中表示,销售菌静态水与注射片一起本身是水用于人类注射的证据,无论标签中的任何一个都说什么.两家机构的公共记录中进行的交叉搜索发现,没有联合FTC/FDA对丸胺,GLP-1或减肥产品的扫描,也没有针对这个窗口的负选反弹道的刑事起诉.FTC和FDA正在针对重叠市场进行单独的码头,并且一个经营商通过FTC审查仍然可以失去一切,因为FDA药品信从未见过.

阿拉巴马州的医疗检查委员会于2026年5月明确表示,任何医生都不能在任何情况下向患者提供"非FDA批准或研究级"的药物,阿拉巴马州检察长关闭并罚款一个打开和关闭在三个月内的病例中,

这些行动中是否有附属公司和媒体买家的名字,

两者都被命名,并且达到附属网络的标准已经解决了司法法.FTC v. LeadClick Media认为该网络为1190万美元的责任,因为它招募了附属公司,批准了他们的登陆页面,支付了他们并给了他们内容的反.

根据TruHeight的2026年投诉,对两个命名的联合首席执行官都应用了相同的控制或参与公式,FTC的合规指导方针明确扩展到广告机构,专家支持者和公司官员的附属网络.Meta已单独起诉该链的工具方面:其2026年的诉讼和停止和弃权信针对伪装供应商和假的"广告恢复"服务,销售逃避作为产品,而不是潜在补充剂的卖家.

支持和证词规则如何按类别执行?

根据FTC的2023年修订的支持指南和2024年审查和证词规则 (16 CFR部分465) 现在单独禁止虚假或人工智能生成的审查,未披露的员工审查和通过法律威胁压制审查.

A disclaimer does not cure a mismatched testimonial claim in any category. FTC's own guidance describes an acne app whose "entertainment purposes only" disclaimer was found "directly contradictory and ineffective," and weight-loss endorsements claiming more than 15 pounds or two-plus pounds a week require an affirmative typical-results disclosure that "results not typical" cannot substitute for. Where a landing page relies on star ratings or review counts rather than a written quote, the same disclosure logic still applies, covered in what the FTC allows on the order page itself.

过去几年,执法人员的姿态发生了什么变化?

截至2021年,有三项突出变化:个人高管现在面临与企业和解一起的刑事暴露,审查欺诈规则被编制成独立的法规,GLP-1和化物营销成为主导的新案例负担.USPlabs和黑石实验室高管在司法部消费者保护部门直接起的案件中获得15至60个月的联邦监禁.

根据美国联邦调查局的"审查和证书规则" (Reviews and Testimonials Rule) 规定,美国联邦调查局首次在每起案件中依赖于虚假评论的直接规则制定权力. 随后,远程健康和化物卖家的警告信件数量大幅上升:FDA在2025年9月份发送了55封信,2026年2月再发送29封信,2026年6月再发送25封信,麦卡里专员说,该机构在前六个月内发出了比整个上十年相结合的误导性广告警告信件更多.

康涅狄格州和阿拉巴马州的总检察长在2025年和2026年之前提出了针对化物和化合物运营商的自己的诉讼,州开始加强医疗法,围绕远程健康和医疗保健模型,使得这种营销成为可能.

运营商如何将此记录转换为基层风险分数?

根据案件记录直接抽取的四个因素进行点:是否指标名称或暗示疾病结果,是否产品接触未经批准或复合药物成分,是否社会证明取决于证词或评论,以及是否按负选项结构进行支付.每个因素独立生成了上述和解或警告信;在一个报价内堆两个或更多的内容是记录集群中最大的判断.

• 疾病或治疗语言存在,即使是指标药物的处方名字:根据FTC第5节和21条CFR 101.93 ((g) 条2分的高风险
• 复合,注射或"仅用于研究"的活性成分:完全忽视意图拒绝使用的FDA药物分类风险
• 证词,前/后图像或星级评级数量推动了报价:在审查规则和支持指南中曝光
• 负期权或自动货运发票,没有明确披露:ROSCA风险投资层次,加上任何潜在的索赔问题
• 附加到MLM结构的收入或收入机会语言:增加了2021年分别的罚款违规通知轨道

运营商应该如何将此记录转换为基层风险分数? (继续)

Reorder-dependent niches carry a second, quieter risk that a static enforcement score misses: a subscription business that survives its first year lives or dies on retention economics that vary sharply by condition, which is why niche selection should weigh reorder behavior by condition alongside the score built above. No score here amounts to legal clearance — treat it as a triage tool for where outside counsel's time gets spent first, not a substitute for that review.

快速决策检查列表

实际问题是,读者是否需要更快的证据来了解已经在VSL驱动的直接反应中发挥作用,特别是在营养品,补充剂,GLP-1,减肥,血糖以及相邻的高意向健康市场上.

对于下一个决定,最重要的是根据市场活动的例子:哪个子要测试,哪个索赔风格有风险,哪个道结构是常见的,哪个语言市场正在移动,以及竞争对手的创意是否可能是早期,扩展或已经和.

• 如果您需要直接答案,请从TL;DR开始.
• 快速比较交易.
• 使用常见问题,以提供答案机准备的总结.
• 根据该决定,使用CTA,而不是理论,需要实时VSL和广告示例.

报道报道报道报道报道报道报道报道报道报道报道报道

广告客户在视觉创意之外所做的事情理解的环境,包括广告客户在黑帽,灰帽和白帽广告模式中,具有足够的背景.实际的区别是,用户不仅看到屏幕截图;他们正在看到VSL,广告,道,转录,UTM文本和将资产转化为决定的研究笔记.

这很重要,因为直接响应的附属公司并不属于一个清洁类别.减肥活动可能使用白帽合规广告,灰帽预登陆器,更具侵略性的VSL和围绕上和恢复设计的收购路径.有用的智能平台需要捕获这种频谱,而不是假装每一次获胜的活动都像公共品牌广告.

黑帽,白帽和多语言信号覆盖

每日英特尔追踪黑帽和白帽式运动的模式,以便运营商能够理解市场而不盲目复制风险.白帽的例子有助于耐用性和合规性审查;黑帽和灰帽的例子揭示了压力点,子,机制和道结构,这些机制可能会推动支出,但需要在使用前仔细的适应.

该目录也为全球运营商构建,VSL和广告引用涵盖14多种语言和不同的当地语法.这对于巴西,拉塔姆,欧洲,MENA,印度和非原生英语附属公司来说是一个关键优势,他们需要看到市场的相同愿望如何跨文化转化,而不是仅仅研究美国英语广告.

如何负责任地使用情报

目标是建模,而不是复制. 使用每日英特尔来了解结构:,机制,证明,要求强度,深度,提供经济学和和阶段.然后构建原创创意,审查要求,并适应角度流量来源,国家,语言和合规要求的竞选.

强大的工作流程在行动之前比较多个例子.如果同一机制在多种语言,多种广告商和多种道变体中出现,它可能是持久的市场信号.如果这个例子只出现一次或依赖于攻击性索赔,请把它视为研究线索而不是竞选模板.

• 模型结构,而不是保护的创意资产.
• 单独的白帽耐用性与黑帽说服压力.
• 比较美国英语的例子与拉塔姆,欧洲和其他语言变体.
• 通过转录和接笔来构建原始简单.
• 保持合规性审查与市场研究分开.

方法论与来源背景

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Alli Weight Loss Pills Alternative: The Honest Replacements, Who Manufactures Semaglutide: The Practical Version, Weight Loss Pills Your Doctor Can Prescribe, Which Weight Loss Products Really Work?, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.